Search
Ladiratuzumab vedotin
go.drugbank.com/drugs/DB15409InvestigationalLadiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
Farudodstat
go.drugbank.com/drugs/DB16049InvestigationalFarudodstat (ASLAN003) is under investigation in clinical trial NCT03451084 (A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia).
ARRY-502
go.drugbank.com/drugs/DB16053InvestigationalARRY-502 is under investigation in clinical trial NCT01561690 (A Study of ARRY-502 in Patients With Persistent Asthma).
Acolbifene
go.drugbank.com/drugs/DB16080InvestigationalAcolbifene is under investigation in clinical trial NCT01452373 (Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women).
Antithrombin gamma
go.drugbank.com/drugs/DB16094InvestigationalAntithrombin gamma is under investigation in clinical trial NCT04182373 (KW-3357 Study in Patients With Early Onset Severe Preeclampsia).
Synonyms: Human antithrombin-iii (atiii, serpin c1) expressed in fucosyl transferase-negative chinese hamster ovary (cho) cells (glycoform gamma)Navicixizumab
go.drugbank.com/drugs/DB12634InvestigationalNavicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Volenrelaxin
go.drugbank.com/drugs/DB21750InvestigationalVolenrelaxin is under investigation in clinical trial NCT06598631 (Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease).
VPM1002
go.drugbank.com/drugs/DB15801InvestigationalVPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other … This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults through post-exposure immunization.
NB-001
go.drugbank.com/drugs/DB12716InvestigationalNB-001 has been investigated for the treatment of Recurrent Herpes Labialis.
GALE-301
go.drugbank.com/drugs/DB17262InvestigationalGALE-301 is an investigational cancer immunotherapy. … It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]